AnaptysBio, Inc. ANAB Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharma Company | $0— | —— | —— | —— | $0— | |
| Royalty Management Company | $25.56M— | —— | —— | —— | $27.77M+21.7% | |
| Nonoperating Income Expense by Business | ||||||
| Biopharma Company | $2.33M— | —— | —— | —— | $4.08M-6.1% | |
| Royalty Management Company | -$20.53M— | —— | —— | —— | -$15.83M-32.8% | |
| Other Nonoperating Income Expense by Business | ||||||
| Biopharma Company | -$1K— | —— | —— | —— | -$7K-300% | |
| Royalty Management Company | $0— | —— | —— | —— | $1.91M— | |
| Net Income Loss by Business | ||||||
| Biopharma Company | -$50.48M— | —— | —— | —— | -$47.2M-15.3% | |
| Royalty Management Company | -$2.4M— | —— | —— | —— | $7.87M+70.3% | |
| Operating Income by Business | ||||||
| Biopharma Company | -$52.81M— | —— | —— | —— | -$51.28M-13.3% | |
| Royalty Management Company | $18.17M— | —— | —— | —— | $23.74M+43.6% | |
| Income Tax Expense Benefit by Business | ||||||
| Biopharma Company | $0— | —— | —— | —— | $0— | |
| Royalty Management Company | $40K— | —— | —— | —— | $44K+5,767% | |
| Interest Income Other by Business | ||||||
| Biopharma Company | $2.33M— | —— | —— | —— | $4.09M-5.9% | |
| Royalty Management Company | $325K— | —— | —— | —— | $322K-46.6% | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest by Business | ||||||
| Biopharma Company | -$50.48M— | —— | —— | —— | -$47.2M-15.3% | |
| Royalty Management Company | -$2.36M— | —— | —— | —— | $7.91M+71.3% | |
| Operating Expenses by Business | ||||||
| Biopharma Company | $52.81M— | —— | —— | —— | $51.28M+13.3% | |
| Royalty Management Company | $7.38M— | —— | —— | —— | $4.03M-35.8% | |
| Research And Development Expense Reversal Excluding Acquired In Process Cost by Business | ||||||
| Biopharma Company | $33.96M— | —— | —— | —— | $41.47M— | |
| Royalty Management Company | $36K— | —— | —— | —— | -$285K— | |
| General And Administrative Expense by Business | ||||||
| Biopharma Company | $18.86M— | —— | —— | —— | $9.82M+36.5% | |
| Royalty Management Company | $7.35M— | —— | —— | —— | $4.32M+26.6% | |
| Noncash Advance Future Royalties Interest Expense by Business | ||||||
| Biopharma Company | $0— | —— | —— | —— | $0— | |
| Royalty Management Company | $20.86M— | —— | —— | —— | $18.06M+44.2% | |
| Revenue by Product | ||||||
| Anaptys Bio Generated Anti PD1Jemperli Dostarlimab | $258M+244% | $75M+50.0% | $50M-62.4% | $133M— | $0-100% | |
| License | $0— | $0— | $0— | $0-100% | $9.6M— | |
| Transaction Service | $100K— | —— | $100K0.0% | $100K0.0% | $100K— | |
| Research And Development Expense Reversal Excluding Acquired In Process Cost by Product | ||||||
| ANB032 | -$31K— | —— | —— | —— | $3.54M— | |
| ANB033 | $9.3M— | —— | —— | —— | $3.8M— | |
| ANB101 | $1.48M— | —— | —— | —— | $1.48M— | |
| External Expenses | $18.66M— | —— | —— | —— | $27.59M— | |
| Imsidolimab | $21K— | —— | —— | —— | -$189K— | |
| Internal Expenses | $15.33M— | —— | —— | —— | $13.59M— | |
| Preclinical And Other Unallocated Costs | $3.3M— | —— | —— | —— | $3.93M— | |
| Rosnilimab | $4.59M— | —— | —— | —— | $15.03M— | |
| General And Administrative Expense by Product | ||||||
| External Expenses | $12.12M+57.0% | $7.72M+244% | $2.25M-7.8% | $2.44M-56.0% | $5.54M+81.5% | |
| Internal Expenses | $14.08M+74.6% | $8.07M+1.3% | $7.96M-2.6% | $8.17M-4.9% | $8.59M+20.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AnaptysBio, Inc. break its business down?
- AnaptysBio, Inc. (ANAB) reports revenue by business across 2 parts — Biopharma Company and Royalty Management Company. Each is extracted from the segment footnotes and tracked over time.
- Where does AnaptysBio, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AnaptysBio, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.